Clinuvel Pharmaceuticals (CLVLY) Stock Price, News & Analysis

Company Overview

Clinuvel Pharmaceuticals is an Australian specialty biopharmaceutical company focused on the development and commercialization of treatments that address genetic, metabolic and life‐threatening disorders through photoprotective and systemic mechanisms. Its research platform centers on melanocortin receptor agonists, which are designed to regulate the body’s natural response to ultraviolet light and reduce cellular damage. Clinuvel’s pipeline extends beyond its lead indication to explore applications in areas such as vitiligo, melanoma and other skin and neurological conditions.

The company’s flagship product, SCENESSE® (afamelanotide), is an implantable formulation approved in the European Union for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). SCENESSE has also received regulatory approval in the United States for the same indication, marking a significant milestone in patient access. In parallel, Clinuvel is conducting clinical trials to assess the efficacy of its technology in additional photosensitive disorders and rare diseases, as well as exploring collaborations and licensing partnerships to broaden its global footprint.

Founded in 1989 and headquartered in Melbourne, Australia, Clinuvel maintains a presence in North America and Europe to support its regulatory, clinical and commercial activities. The company is led by Managing Director and Chief Executive Officer Philippe Wolgen, backed by a board of directors and a management team with expertise in drug development, regulatory affairs and commercial operations. Clinuvel continues to invest in research and strategic alliances to advance its mission of delivering innovative therapies to patients with high unmet medical needs.

Key Stats

• Today's Range: $7.18 to $7.18
• 50-Day Range: $6.20 to $7.22
• 52-Week Range: $6.00 to $10.70
• Volume: 828 shs
• Average Volume: 2,151 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CLVLY Stock Analysis - Frequently Asked Questions

How have CLVLY shares performed this year?

Clinuvel Pharmaceuticals' stock was trading at $7.70 at the beginning of the year. Since then, CLVLY shares have decreased by 6.8% and is now trading at $7.18.

How do I buy shares of Clinuvel Pharmaceuticals?

Shares of CLVLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/18/2025
• Next Earnings (Estimated): 8/17/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:CLVLY
• CIK: 1290877
• Web: www.clinuvel.com
• Phone: (139) 660-4900
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A